Gilead Sciences Inc. (GIS)
Summary
GIS Chart
Gilead's twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)'s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being officially approved by the US Food and Drug Administration (FDA) on Wednesday, analysts at Jefferies believe. Lenacapavir, marketed as Yeztugo, is the first pre-exposure prophylaxis (PrEP) drug requiring only two treatments per year, offering a significant convenience advantage over daily oral PrEP and cabotegravir, which requires six injections per year.
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP. Data show that ≥99.9% of partici.
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending the decades-long epidemic caused by the virus.
Gilead Sciences Inc. Dividends
| GIS 5 days ago | Other | €0.68 Per Share |
| GIS 3 months ago | Other | €0.68 Per Share |
| GIS 6 months ago | Other | €0.67 Per Share |
| GIS 9 months ago | Other | €0.67 Per Share |
| GIS 14 Jun 2024 | Other | €0.67 Per Share |
Gilead Sciences Inc. Earnings
| 6 Aug 2025 (49 Days) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| GIS 5 days ago | Other | €0.68 Per Share |
| GIS 3 months ago | Other | €0.68 Per Share |
| GIS 6 months ago | Other | €0.67 Per Share |
| GIS 9 months ago | Other | €0.67 Per Share |
| GIS 14 Jun 2024 | Other | €0.67 Per Share |
| 6 Aug 2025 (49 Days) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
Gilead Sciences Inc. (GIS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Gilead Sciences Inc. ever had a stock split?
Gilead Sciences Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Daniel P. O'Day CEO | XDUS Exchange | US3755581036 ISIN |
| US Country | 17,600 Employees | 14 Mar 2025 Last Dividend | 28 Jan 2013 Last Split | 22 Jan 1992 IPO Date |
Overview
Gilead Sciences, Inc. is a frontline biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company's mission revolves around addressing unmet medical needs across the United States, Europe, and other international markets. Since its inception in 1987, Gilead Sciences has been committed to pushing the boundaries of scientific research to create therapeutic solutions that can significantly improve the quality of life for patients worldwide. With its headquarters in Foster City, California, Gilead stands as a pioneer in the field, forming strategic collaboration agreements with various entities including Arcus Biosciences, Inc., Merck Sharp & Dohme Corp., and many others to bolster its research and development efforts. The company's extensive portfolio underscores its dedication to combating some of today's most challenging diseases, including HIV/AIDS, COVID-19, viral hepatitis, and certain oncological disorders.
Products and Services
- HIV/AIDS treatment:
- COVID-19:
- Viral Hepatitis:
- Oncology:
- Pulmonary Arterial Hypertension:
- Severe Fungal Infections:
Gilead provides a robust lineup of products for HIV/AIDS management, including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla. Each of these treatments plays a vital role in suppressing the virus, improving patient health, and reducing the risk of HIV transmission.
Veklury (Remdesivir) serves as an injection for intravenous use designed to treat COVID-19. It represents one of the first antiviral treatments to receive emergency use authorization for addressing the global pandemic, demonstrating efficacy in helping hospitalized patients recover faster.
Gilead offers Epclusa, Harvoni, Vemlidy, and Viread for the treatment of hepatitis B and C, contributing to the global effort to manage and potentially eliminate viral hepatitis as a major public health threat.
The company has made significant strides in cancer treatment with its products Yescarta, Tecartus, and Trodelvy, focusing on innovative therapies that can potentially transform the treatment landscape for patients suffering from various cancers.
Letairis is an oral medication developed for the treatment of pulmonary arterial hypertension (PAH), aiming to improve exercise ability and delay clinical worsening in patients.
AmBisome, a liposomal formulation, is targeted at treating serious invasive fungal infections, offering a critical solution for immunocompromised patients such as those undergoing chemotherapy or with HIV/AIDS.
Across these diverse therapeutic areas, Gilead Sciences maintains a steadfast commitment to innovation, safety, and efficacy, striving to fulfill its mission of advancing healthcare and enhancing patient outcomes around the globe.
Contact Information
